Latest Doxycycline Stories

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg, following a favorable decision by the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Warner Chilcott. The Court held, after trial, that Mylan's product does not infringe the subject patent. Mylan is shipping product immediately....

A combined therapy of common acne medications was shown to be a potent regimen for treating patients with severe facial acne, according to two published studies involving Henry Ford Hospital. The companion studies found that a therapy of the topical Epiduo Gel containing adapalene and benzoyl peroxide and the antibiotic doxycycline proved more effective at reducing acne lesions compared to other treatment regimens. Of the 459 patients involved in the study, 76 percent of those who...

PITTSBURGH, Feb. 9, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-release (DR) Tablets USP, 150 mg. This product is the generic version of Mayne Pharma's Doryx® (marketed by Warner Chilcott), which is a tetracycline-class antimicrobial. Mylan CEO...

RICHMOND, Texas, April 28, 2011 /PRNewswire/ -- OCuSOFT, Inc., an ophthalmic research, development, and supply company is pleased to announce the availability of prescription-only (Rx) Ocudox(TM) Convenience Kit for immediate dispensing at most retail pharmacies including, but not limited to: Walgreens, CVS, Wal-Mart, Rite Aid and Duane Reade. The Ocudox(TM) Convenience Kit contains Ocudox(TM) (Doxycycline Hyclate 50 mg, 60 Capsules, USP), OCuSOFT® Lid Scrub(TM) PLUS Extra Strength...

The 2001 anthrax attacks in the United States are fostering development of a new generation of vaccines, antibiotics, and other medications to protect people against the potentially deadly bacteria in any future bioterrorist incident. That's the conclusion of a sweeping overview of scientific research on medical technology to combat the anthrax threat. It appears in ACS' bi-weekly Journal of Medicinal Chemistry.In the article, Dimitrios Bouzianas notes that several existing antibiotics are...

Controversial treatment approach could lead to a cureResearchers from University of South Florida College of Medicine found a combination of antibiotics to be an effective treatment for Chlamydia-induced reactive arthritis, a major step forward in the management, and possibly cure, of this disease. Results of this study are published in the May issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology.Reactive arthritis (ReA), also known as Reiter's syndrome,...

A new study in Bangladesh suggests tigecycline -- the first member of a new class of antibiotics -- might be effective against multi-drug-resistant malaria. Researchers said tigecycline shows significant anti-malarial activity on its own and can be administered in combination with traditional anti-malarial drugs. The increasing drug resistance of Plasmodium falciparum, one of the parasites that cause malaria, has resulted in the search for new anti-malarial therapies. The scientists said...

PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA). Mylan and Alphapharm Pty. Ltd were sued by Sepracor Inc. in the U.S. District Court of New Jersey in connection with the ANDA filing for Eszopiclone Tablets, 1 mg, 2 mg and 3 mg. Eszopiclone Tablets are the generic...

RICHMOND, Texas, Dec. 3 /PRNewswire/ -- CYNACON/OCuSOFT, a broad based supplier of ophthalmic pharmaceuticals and supplies, is pleased to announce a new partnership with Eye Eco, Inc. Tranquileyes(TM) Moist Heat Therapy Goggles and Thermoeyes(TM) Reusable Heat Packs, from Eye Eco, Inc. are now included in OCuSOFT's prescription only low-dose doxycycline ALODOX(TM) Convenience Kit for adjunctive eyelid therapy and hygiene. (Photo:...

Nanotherapeutics, a privately held specialty biopharmaceutical company, announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX(TM) Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomized double-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcers of the lower extremity. Assuming FDA approval, the Company...